pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,043 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT774Endpoints578BioPharma Dive223onclive165BioSpace52Fierce Biotech52raps22
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • Make or break: Commercial hires critical for success
    With the stakes for successful launches high, and demand for commercial roles increasing, biopharmas must thoughtfully approach not only hiring but also retention. During a BioSpace webinar, experi…
    BioSpace · 1d ago↗ source
  • Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
    With fewer biopharmas making or planning workforce reductions so far year over year, layoff round size and M&A impact on headcounts will likely shape the number of employees who are ultimately on t…
    BioSpace · 1d ago↗ source
  • Australian biopharma Clinuvel to shed up to 20% of workforce in move to US
    Australian biopharma Clinuvel Pharmaceuticals is moving its headquarters to the U.S.— but up to a fifth of the company’s workforce won’t be staying for the trans-Pacific pivot.
← prev
page 3 of 42
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Fierce Biotech · 1d ago
↗ source
  • Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
    Roche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told Fierce that still has a strategy for developing cell therapies for autoimmune disea…
    Fierce Biotech · 1d ago↗ source
  • FDA clears Johnson & Johnson’s surgical robot for ‘the next era in surgery’
    The FDA has authorized Johnson & Johnson’s Ottava Robotic Surgical System as the company looks to compete with Intuitive Surgical and Medtronic.
    Fierce Biotech · 1d ago↗ source
  • STAT+: What is a ‘world model’? Nabla’s Alex LeBrun explains
    In this edition of AI Prognosis, Brittany Trang talks to Alex LeBrun, AI scribe company Nabla's executive chairman, about an alternative to LLMs
    STAT · 1d ago↗ source
  • New study supports testing of Merck’s Ebola vaccine in DRC outbreak
    New data supports the idea that Merck’s Ebola vaccine Ervebo, licensed to target the Zaire species of ebolaviruses, could also offer some protection against another.
    STAT · 1d ago↗ source
  • Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
    This webinar provides an assessment of recent job market activity across biopharma and explores how companies approaching commercial readiness or building out sales and marketing teams can navigate…
    BioSpace · 1d ago↗ source
  • Opinion: What Argentina’s World Cup loss should teach American hospitals
    “Hospitals often make Argentina’s mistake: We confuse continuity with progress,” writes physician, hospital administrator, and bioethicist Basel Tarab.
    STAT · 2d ago↗ source
  • Summit and Akeso sharpen case for ivonescimab with new Western data
    Summit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistic…
    BioSpace · 2d ago↗ source
  • Congo’s Ebola outbreak has killed over 1,000 people
    At least 999 people have died from the Ebola outbreak in Congo, a grim toll in what’s already been declared the fastest Ebola outbreak in history.
    STAT · 2d ago↗ source
  • NIH joins Trump’s $5B AI mission with biomedical research push
    The U.S. Department of Health and Human Services announced new efforts Wednesday aligned with President Donald Trump’s artificial intelligence-driven Genesis Mission. The centerpiece of HHS’ partic…
    Fierce Biotech · 2d ago↗ source
  • Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
    With Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follo…
    BioSpace · 2d ago↗ source
  • STAT+: Pharma tries to tamp down broad China restrictions
    AI-focused VC firm raises $800M, Merck's new cholesterol pill, and more biotech news from The Readout
    STAT · 2d ago↗ source
  • Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
    Top-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.
    BioSpace · 2d ago↗ source
  • 6 companies hiring in Cambridge now
    Looking for a biopharma job in Cambridge? Roles posted on BioSpace have more than doubled compared to last year.
    BioSpace · 2d ago↗ source
  • STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and more
    President Trump plans to impose tariffs on imported generic medicines, his latest threat aimed at bringing pharmaceutical manufacturing back to the U.S.
    STAT · 2d ago↗ source
  • US ‘eroding’ lead in rare diseases a matter of national security: Report
    A Congressional advisory panel recommends the U.S. government put supportive policies in place for rare disease drug development, such as a finalized platform designation from the FDA and the allow…
    BioSpace · 2d ago↗ source
  • Job dissatisfaction and health care access uncertainty grows in the U.S., new study finds
    What Hawaii's wildfires can teach the nation about health recovery, 4.5 million people disenrolled from SNAP, and more health news
    STAT · 2d ago↗ source
  • 2026 IPO stock tracker: How newly public biotechs are performing
    BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.
    BioSpace · 2d ago↗ source
  • Novartis scraps mid-stage radiopharma asset as Pluvicto soars
    The discontinued asset, being trialed for breast cancer and solid tumors, had yielded disappointing data, leading to Novartis’ decision to abandon development, according to a company spokesperson.
    BioSpace · 2d ago↗ source
  • Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
    Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics spa…
    BioSpace · 2d ago↗ source
  • House passes bill directing FDA to update animal testing rules
    The U.S. House of Representatives passed the FDA Modernization Act 3.0 this week, and lawmakers and animal welfare advocates are celebrating the bill as a step toward a new era in preclinical testi…
    Fierce Biotech · 2d ago↗ source
  • STAT+: ‘Cochlear implant for blindness’ debuts in Europe, could launch in U.S. in 2027
    Science Corporation announced the European launch of its retinal implant for patients with age-related macular degeneration.
    STAT · 2d ago↗ source
  • Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug
    Royalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca-partnered med.
    Fierce Biotech · 2d ago↗ source